精神分裂症或双相障碍家族高危儿童神经认知发育研究
丹麦高危与韧性研究为前瞻性纵向队列,纳入520名精神分裂症或双相障碍家族高危儿童及人群对照,评估7至11岁神经认知发育。校正多重比较后三组间无显著时间×组交互;精神分裂症高危组在24项中有7项显著受损,双相障碍高危组与对照无显著差异。
要点
- 精神分裂症高危儿童7至11岁神经认知成熟轨迹与对照相当,但存在广泛稳定的认知损害。
- 双相障碍高危儿童与人群对照在神经认知各项测量上无显著差异。
- 三组间神经认知随时间变化的交互作用经多重比较校正后均未达统计学显著。
核心结论
- 从7岁至11岁,精神分裂症或双相障碍家族高危儿童的神经认知成熟与人群对照儿童相当。
- 与人群对照相比,精神分裂症高危儿童在该时期表现出广泛、稳定的神经认知损害,而双相障碍高危儿童未显示神经认知损害,可能提示两者神经发育通路不同。
研究设计与样本
- 丹麦高危与韧性研究为前瞻性纵向队列研究,数据采集于2013年1月1日至2016年1月31日(第一阶段)及2017年3月1日至2020年6月30日(第二阶段)。
- 数据采集于丹麦2所大学医院,纳入520名精神分裂症或双相障碍家族高危儿童,以及按年龄、性别和市镇与精神分裂症高危组匹配的人群对照。
主要发现
- 4年随访时共451名儿童接受神经认知测试(平均[SD]年龄11.9[0.2]岁;208名女孩[46.1%])。
- 精神分裂症高危组170名(平均[SD]年龄12.0[0.3]岁;81名女孩[47.7%]),双相障碍高危组103名(平均[SD]年龄11.9[0.2]岁;45名女孩[43.7%]),人群对照组178名(平均[SD]年龄11.9[0.2]岁;82名女孩[46.1%])。
- 在7岁或11岁或两次评估均参与的520名儿童被纳入分析;校正多重比较后,三组间未观察到统计学显著的时间×组交互作用。
- 4年随访时与人群对照组相比,精神分裂症高危组在24项神经认知测量中的7项(29.2%;Cohen d范围0.29-0.37)显示显著神经认知损害。
- 与双相障碍高危组相比,精神分裂症高危组在24项测量中的5项(20.8%;Cohen d范围0.29-0.38)显示显著神经认知损害;双相障碍高危组与人群对照组无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neurocognitive impairments exist in children at familial high risk (FHR) of schizophrenia and bipolar disorder. Studies on preadolescent developmental courses of neurocognition are important to describe shared and distinct neurodevelopmental pathways in these groups. OBJECTIVE: To assess the development in specific neurocognitive functions from age 7 to 11 years in children at FHR of schizophrenia or bipolar disorder compared with children in a population-based control (PBC) group. DESIGN, SETTING, AND PARTICIPANTS: The Danish High Risk and Resilience Study is a prospective, longitudinal, cohort study that collected data from January 1, 2013, to January 31, 2016 (phase 1), and from March 1, 2017, to June 30, 2020 (phase 2). Data were collected at 2 university hospitals in Denmark, and participants included 520 children at FHR of schizophrenia or bipolar disorder along with a PBC group matched with the group of children at FHR of schizophrenia by age, sex, and municipality. EXPOSURES: Parental schizophrenia, bipolar disorder, or neither. MAIN OUTCOMES AND MEASURES: Neurocognitive functioning was assessed with validated tests of intelligence, processing speed, attention, memory, verbal fluency, and executive functioning. Multilevel mixed-effects linear regression models with maximum likelihood estimation were used to estimate neurocognitive development from age 7 to 11 years. RESULTS: At 4-year follow-up, a total of 451 children (mean [SD] age; 11.9 [0.2] years; 208 girls [46.1%]) underwent neurocognitive testing. There were a total of 170 children at FHR of schizophrenia (mean [SD] age, 12.0 [0.3]; 81 girls [47.7%]), 103 children at FHR of bipolar disorder (mean [SD] age, 11.9 [0.2] years; 45 girls [43.7%]), and 178 children in the PBC group (mean [SD] age, 11.9 [0.2] years; 82 girls [46.1%]). At either age 7 or 11 years or at both assessments, 520 children participated in the neurocognitive assessment and were therefore included in the analyses. When correcting for multiple comparisons, no statistically significant time × group interactions were observed across the 3 groups. Compared with the PBC group at 4-year follow-up, children at FHR of schizophrenia showed significant neurocognitive impairment in 7 of 24 neurocognitive measures (29.2%; Cohen d range, 0.29-0.37). Compared with children at FHR of bipolar disorder, children at FHR of schizophrenia had significant neurocognitive impairment in 5 of 24 measures (20.8%; Cohen d range, 0.29-0.38). Children at FHR of bipolar disorder and those in the PBC group did not differ significantly. CONCLUSIONS AND RELEVANCE: In this cohort study, findings suggest that neurocognitive maturation was comparable across groups of children at FHR of schizophrenia or bipolar disorder compared with PBCs from age 7 to 11 years. Compared with the PBC group, children at FHR of schizophrenia demonstrated widespread, stable, neurocognitive impairments during this period, whereas children at FHR of bipolar disorder showed no neurocognitive impairments, which may indicate distinct neurodevelopmental pathways in children at FHR of schizophrenia and bipolar disorder.
引用
- Knudsen CB, Hemager N, Greve AN, et al. Neurocognitive Development in Children at Familial High Risk of Schizophrenia or Bipolar Disorder. JAMA Psychiatry. 2022. PMID: 35385060. doi:10.1001/jamapsychiatry.2022.0465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。